$143.37
Value $354B
MRK and PLX stock compared: price, dividend, valuation and results, from SEC filings.
$143.37
Value $354B
$2.88
Value $232M
Merck & Company (MRK) has a market value of $354B and Protalix BioTherapeutics (PLX) $232M. Over the last year, with dividends, MRK moved +60.0% and PLX +62.9%. The P/E is 144.5 for MRK and 11.3 for PLX. Dividend yield: MRK 2.37%, PLX none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MRK$354B
PLX$232M
MRK is 1,528 times PLX
Revenue, 12 months
MRK$67.4B
PLX$85M
MRK is 796 times PLX
Net income, 12 months
MRK$2.5B
PLX$21M
MRK is 119 times PLX
Operating margin
MRK–
PLX29.8%
ROIC
MRK3.9%
PLX31.3%
27.4 points apart
P/E
MRK144.5
PLX11.3
MRK is 13 times PLX
Dividend yield
MRK2.4%
PLX0.0%
2.4 points apart
5-year return
MRK+101.1%
PLX+163.5%
62.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
MRK+101.1%
PLX+163.5%
| Period | MRKWith dividends | PLXWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +60.0%Price +55.5% | +62.9%Price +62.9% |
| 3 years since November 16, 2023 | +55.2%+15.8% a yearPrice +41.6% | +118.0%+29.7% a yearPrice +118.0% |
| 5 years since November 15, 2021 | +101.1%+15.0% a yearPrice +72.6% | +163.5%+21.4% a yearPrice +163.5% |
| 10 years since November 17, 2016 | +227.6%+12.6% a yearPrice +141.5% | -38.2%-4.7% a yearPrice -38.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
MRKMerck & CompanyPLXProtalix BioTherapeutics
| Price | $143.37 | $2.88 |
|---|---|---|
| Market value | $354B | $232M |
| Enterprise value (EV) | $399B | $210M |
| P/E | 144.5 | 11.3 |
| P/E, 5-year median | 14.8 | – |
| P/B | 7.9 | 2.9 |
| EV/EBIT | 83.7 | 8.3 |
| Free cash flow yield | 4.2% | 6.5% |
| Revenue, 12 months | $67.4B | $85M |
|---|---|---|
| Net income, 12 months | $2.5B | $21M |
| Free cash flow, 12 months | $14.7B | $15M |
| Earnings per share, 12 months | $0.98 | $0.25 |
| Revenue growth, year on year | 1.3% | -1.2% |
| Revenue growth a year, past | +9.4%over 5 years | -3.5%over 5 years |
| EPS growth a year, past | +21.2%over 5 years | – |
| Gross margin | 71.8% | 71.2% |
|---|---|---|
| Operating margin | – | 29.8% |
| Net margin | 3.6% | 24.3% |
| ROIC | 3.9% | 31.3% |
| ROE | 5.2% | 32.1% |
| Cash | $9.7B | $22M |
|---|---|---|
| Total debt | $53.8B | $9.1M |
| Net debt / EBITDA | 5.7 | -0.8 |
| Interest cover | 2.4× | – |
| Dividend yield | 2.4% | – |
|---|---|---|
| Dividend per share, 12 months | $3.40 | – |
| Dividend growth a year, past | +5.8%over 5 years | – |
| Buyback yield | 1.4% | – |
| Shareholder yield | 3.8% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($354B) is about 1,527.6 times Protalix BioTherapeutics ($232M), at today's prices.
Since November 17, 2016, MRK's price moved +141.5% and PLX's -38.2%. With dividends: MRK +227.6% (+12.6% a year), PLX -38.2% (-4.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.37% for Merck & Company and none for Protalix BioTherapeutics. Over the last twelve months they paid $3.40 and – per share.
At today's price, the P/E is 144.5 for MRK and 11.3 for PLX. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 3.6% for Merck & Company and 24.3% for Protalix BioTherapeutics, and the operating margin – and 29.8%. Revenue was $67.4B and $85M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.